Funding option: royalties giant opens Hong Kong base as mainland China biotech deals surge
AI Summary
The largest buyer of biopharmaceutical royalties has established its first Asia-Pacific base in Hong Kong amidst a surge in mainland Chinese biotech deals. This expansion supports alternative financing routes for Chinese drug developers amid US investment restrictions.
The worldβs largest buyer of biopharmaceutical royalties has set up its first Asia-Pacific base in Hong Kong, joining a string of multinational corporations in the pharmaceutical sector establishing offices in the city as out-licensing deals by mainland Chinese biotechnology firms hit record highs. Royalty financing gives drug developers an alternative way to raise capital even as US investment restrictions loom, according to an expert. βChinese biotech firms would need royalty financing as an...